logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Avidity Biosciences, Inc.


USPTO Granted Patents = 54



Forward Citations = 387

Loading Chart...
Loading Chart...

26 inventors (with patents filed for the assignee):

goldMedal Rob Burke (41 out of 44 patents)

silverMedal Venkata Ramana Doppalapudi (37 out of 44 patents)

bronzeMedal Beatrice Diana Darimont (37 out of 37 patents)

4.  Michael Caramian Cochran (35 out of 37 patents)

5.  Barbora Malecova (27 out of 27 patents)

6.  Andrew John Geall (25 out of 101 patents)

7.  David Sai-Ho Chu (21 out of 21 patents)

8.  Yunyu Shi (15 out of 15 patents)

9.  Gulin Erdogan Marelius (14 out of 19 patents)

10.  Michael David Hood (14 out of 14 patents)

11.  David Sala Cano (10 out of 10 patents)

12.  Rachel Elizabeth Johns (9 out of 9 patents)

13.  Hanhua Huang (8 out of 8 patents)

14.  Palani Balu (6 out of 14 patents)

15.  Arthur A Levin (5 out of 5 patents)


Core Competencies:
Muscle Dystrophy
Cardiomyopathy
Nucleic Acid-Polypeptide Compositions
Exon Skipping
Anti-Transferrin Receptor Antibodies
Facioscapulohumeral Muscular Dystrophy
Muscle Atrophy
Myotonic Dystrophy
PLN-Targeting Antibodies
Una Amidites
EGFR Nucleic Acids
KRAS Nucleic Acids

54 patents:

1. 12708669 - POLYNUCLEOTIDE CONJUGATES COMPRISING PLN-TARGETING POLYNUCLEOTIDES AND ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHOD OF USE THEREOF TO TREAT PLN-ASSOCIATED CARDIOMYOPATHIES (2026-08-18),
2. 12648999 - COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY (2026-06-09),
3. 12648998 - ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING (2026-06-09),
4. 12529056 - COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (2026-01-20),
5. 12497615 - NUCLEIC ACID COMPOSITIONS AND METHODS OF MULTI-EXON SKIPPING (2025-12-16),
6. 12491257 - COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES (2025-12-09),
7. 12486328 - COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (2025-12-02),
8. 12427202 - Compositions and methods of treating muscle dystrophy (2025-09-30),
9. 12409230 - Compositions comprising PLN-targeting anti-transferrin receptor antibody-polynucleotides and methods of use thereof to treat cardiomyopathy (2025-09-09),
10. 12365704 - Nucleic acid-polypeptide compositions and uses thereof (2025-07-22),
11. 12364769 - Nucleic acid-polypeptide compositions and uses thereof (2025-07-22),
12. 12359202 - Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping (2025-07-15),
13. 12351637 - Nucleic acid-polypeptide compositions and uses thereof (2025-07-08),
14. 12263224 - Compositions and methods of treating muscle atrophy and myotonic dystrophy (2025-04-01),
15. 12234290 - Nucleic acid-polypeptide compositions and uses thereof (2025-02-25),
Avidity Biosciences is a biotechnology company focused on the development of targeted therapies for the treatment of rare muscle disorders. They are pioneering a proprietary technology platform called AOCs (Arcus™ Occurrence Catalytic System) that enables the targeted delivery of nucleic acids to muscle tissue. Avidity Biosciences is dedicated to advancing its pipeline of potential therapies to address the unmet needs of patients with rare muscle diseases.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Avidity Biosciences, Inc.
54 Patents

#114 in San Diego, CA

#1,541 in California

#6,549 in US

#13,100 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Avidity Biosciences, Inc.

Forward Citations = 387

26 inventors:

goldMedal Rob Burke (41 out of 44 patents)

silverMedal Venkata Ramana Doppalapudi (37 out of 44 patents)

bronzeMedal Beatrice Diana Darimont (37 out of 37 patents)

4.  Michael Caramian Cochran (35 out of 37 patents)

5.  Barbora Malecova (27 out of 27 patents)

Please report any incorrect information to [email protected]
Loading…